ARS Pharma称英国MHRA批准EURneffy用于紧急治疗体重超过30公斤的成人和儿童的过敏反应

EURneffy (neffy® in the U.S.) offers a new delivery method for adrenaline in the U.K. for adults and children (>30 kg) living with severe allergic reactions

ALK-Abelló A/S, which owns the rights to market EURneffy in the U.K., expects availability in late Q3 2025

U.K. is the largest market outside the U.S. for adrenaline (epinephrine) auto-injector sales

SAN DIEGO, July 18, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, announced today that the United Kingdom (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for EURneffy (adrenaline nasal spray) for the emergency treatment of allergic reactions (anaphylaxis) in adults and children who weigh greater than 30 kg.